Significant reduction in the emergence of contralateral breast cancer in all current adjuvant studies of third generation aromatase inhibitors raises the question of whether they might have a role in disease prevention, particularly bearing in mind their favourable safety/tolerability profile, an especially important consideration in this setting. The gene discussed is CYP19A1; the disease is breast carcinoma.